Cancers | Free Full-Text | Artificial Intelligence Predicted Overall Survival and Classified Mature B-Cell Neoplasms Based on Immuno-Oncology and Immune Checkpoint Panels
Kaplan-Meier survival curves of a progression-free survival (PFS) and b... | Download Scientific Diagram
Retrospective observational cohort study on innovation in oncology and progress in survival: How far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a
Diagnostics | Free Full-Text | Prognostic Factors Associated with 5-Year Overall Survival in Cervical Cancer Patients Treated with Radical Hysterectomy Followed by Adjuvant Concurrent Chemoradiation Therapy at a Tertiary Care Center in
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
Overall survival for chemotherapy-treated and-untreated patients with... | Download Scientific Diagram
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis - Katrin M. Sjoquist, Sarah J. Lord, Michael L. Friedlander, Robert John Simes, Ian C. Marschner,
SOLO-2: Overall Survival Data on Olaparib for Relapsed, BRCA-Mutated Ovarian Cancer
Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing r
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer | NEJM
Oncotarget: Melatonin increases overall survi | EurekAlert!
Overall survival (OS) curves in each gastric cancer (GC) pathological... | Download Scientific Diagram
Prognostic factors in epithelial ovarian cancer: A population-based study | PLOS ONE
Overall survival and breast-cancer-specific survival curves according... | Download Scientific Diagram
Peregrine Pharmaceuticals, Inc. Drug Doubles Lung Cancer Survival in Trial | BioSpace
Cancer - Our World in Data
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer | BMC Cancer | Full Text
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status | Journal for ImmunoTherapy of Cancer
The role of censoring on progression free survival: Oncologist discretion advised - ScienceDirect
Pancancer survival analysis of cancer hallmark genes | Scientific Reports
Figure 1 from Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. | Semantic Scholar
